awmsg logo



glecaprevir/pibrentasvir (Maviret®)


Reference No. 3917


Appraisal information

glecaprevir/pibrentasvir (Maviret®) 100 mg/40 mg film-coated tablet


Company: AbbVie Ltd
BNF category: Infections
NMG meeting date: 04/09/2019
AWMSG meeting date: 16/10/2019
   
   
Submission Type: Limited Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of chronic hepatitis C virus (HCV) infection in adolescents aged 12 to <18 years
AWMSG Secretariat Appraisal Report (ASAR)
Download
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download